Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: A retrospective cohort study

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Berger, Ariel ^a   Edelsberg, John ^a   Bollu, Vamsi ^b   Alvir, Jose Ma J ^c   Dugar, Ashish ^c   Joshi, Ashish V ^c   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; ANXIOLYTIC AGENT;

ARTICLE; COHORT ANALYSIS; DATA BASE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; INTERNATIONAL CLASSIFICATION OF DISEASES; RETROSPECTIVE STUDY; UNITED STATES; ADULT; AGED; ANXIETY DISORDER; DRUG COST; ECONOMICS; FACTUAL DATABASE; FEMALE; HEALTH CARE DELIVERY; HUMAN; MALE; MIDDLE AGED; UTILIZATION REVIEW;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DATABASES, FACTUAL; DELIVERY OF HEALTH CARE; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 83155178491     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-193     Document Type: Article

References (23)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Text Revision 2000, Washington, DC: American Psychiatric Association, Fourth, American Psychiatric Association.
2. Kessler R, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age of onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:593-602. 10.1001/archpsyc.62.6.593, 15939837.
3. Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005, 15:445-452. 10.1016/j.euroneuro.2005.04.010, 15951160.
4. Wittchen HU, Carter RM, Pfister H, Montgomery SA, Kessler RC. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 2000, 15:319-328. 10.1097/00004850-200015060-00002, 11110007.
5. Ormel J, VonKorff M, Ustun TB, Pini S, Korten A, Oldehinkel T. Common mental disorders and disability across cultures: Results from the WHO collaborative study on psychological problems in general health care. JAMA 1994, 272:1741-1748. 10.1001/jama.1994.03520220035028, 7966922.
6. Wittchen HU. Generalized anxiety disorder: Prevalence, burden, and cost to society. Depress Anxiety 2002, 16:162-171. 10.1002/da.10065, 12497648.
7. Munk-Jorgensen P, Allgulander C, Dahl AA, Foldager L, Holm M, Rasmussen I, Virta A, Huuhtanen MT, Wittchen HU. Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden. Psychiatr Serv 2006, 57:1738-1744. 10.1176/appi.ps.57.12.1738, 17158488.
8. Yonkers KA, Dyck IR, Warshaw M, Keller MB. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry 2000, 176:544-549. 10.1192/bjp.176.6.544, 10974960.
9. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JRT, den Boer JA, Fineberg NA, Knapp M, Scott J, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005, 19:567-596. 10.1177/0269881105059253, 16272179.
10. Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Borkovec TD, Rickels K, Stein DJ, Wittchen HU. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001, 62(Suppl 11):53-58.
11. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993, 328:1398-1405. 10.1056/NEJM199305133281907, 8292115.
12. Gorman JM. Treating generalized anxiety disorder. J Clin Psychiatry 2003, 64(Suppl 2):24-29.
13. Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 2003, 8(Suppl 1):53-61.
14. Michael Kaplan E, DuPont RL. Benzodiazepines and anxiety disorders: A review for the practicing physician. Curr Med Res Opin 2005, 21:941-950. 10.1185/030079905X48401, 15969894.
15. Lader M. Effectiveness of benzodiazepines: Do they work or not?. Exp Rev Neurother 2008, 8:1189-1191.
16. Francois C, Despiegel N, Maman K, Saragoussi D, Auguier P. Anxiety disorders, major depressive disorder and the dynamic relationship between these conditions: treatment patterns and cost analysis. J Med Econ 2010, 13:99-109. 10.3111/13696991003591321, 20078336.
17. Benítez CIP, Vasile RG, Edelen MO. Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders. Am J Geriatr Psychiatry 2008, 16:5-13. 10.1097/JGP.0b013e31815aff5c, 18165458.
18. Vasile RG, Bruce SE, Goisman RM, Pagano M, Keller MB. Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depress Anxiety 2005, 22:59-67. 10.1002/da.20089, 16094662.
19. Stein MB, Cantrell CR, Sokol MC, Eaddy MT, Shah MB. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatric Serv 2006, 57:673-680.
20. Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharm 2005, 8:293-302.
21. Zohar J, Westenberg HG. Anxiety disorders: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatrica Scan 2000, 101(Suppl 403):39-49.
22. Hoffman EJ, Mattew SJ. Anxiety disorders: A comprehensive review of pharmacotherapies. Mt Sinai J Med 2008, 75:248-262. 10.1002/msj.20041, 18704983.
23. Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 2005, 10:49-56.